We evaluated longitudinal rates of Kaposi's sarcoma and trends in CD4 cell counts at the time of Kaposi's sarcoma diagnosis during the HIV epidemic . Although rates of Kaposi's sarcoma have decreased, cases are now occurring at higher CD4 cell counts over time, with more than onethird of cases diagnosed in 2002-2008 occurring at CD4 cell counts of at least 350 cells/ml. These data support future studies evaluating the impact of highly active antiretroviral therapy initiation at higher CD4 cell counts to further reduce Kaposi's sarcoma.
During the HIV epidemic, the types and presentations of cancers have dramatically changed [1] [2] [3] [4] . As an AIDSdefining cancer, most Kaposi's sarcoma cases have traditionally occurred at low CD4 cell counts (<200 cells/ml) [5, 6] . Although Kaposi's sarcoma rates have decreased [7] , it is unknown whether Kaposi's sarcoma will now be observed at higher CD4 cell counts.
We evaluated Kaposi's sarcoma rates and trends in CD4 cell counts at Kaposi's sarcoma diagnosis among HIVinfected persons using the US Military HIV Natural History Study [3, 8] . The diagnosis of Kaposi's sarcoma was based on medical record review using standardized criteria [3] . Rates and rate ratios (overall and for time spent with CD4 cell count <350 and !350 cells/ml) with 95% confidence intervals (CI) were calculated with Poisson regression models for four a priori defined calendar periods (1985-1990, 1991-1995, 1996-2001, and 2002-2008) . Participants contributed follow-up time to all possible calendar periods from baseline (6 months prior to HIV diagnosis) to the event or censoring time (last study visit). Among those with Kaposi's sarcoma and a proximal CD4 cell count (within 1 year prior to Kaposi's sarcoma diagnosis), participants were compared by proximal CD4 cell count category (<350 versus !350 cells/ml) with descriptive statistics (chi-squared and Wilcoxon tests) as appropriate. Medians are presented with interquartile ranges (IQR). We also evaluated factors associated with Kaposi's sarcoma during the highly active antiretroviral therapy (HAART) era (the latest of 1 January 1996 or HIV diagnosis date) with timeupdated proportional hazards models.
There were 5067 participants with 39 522 person-years of follow-up between 1985 and 2008. At HIV diagnosis, the median age was 28 (IQR 24-34) years; 92% were men; 45% were African American and 43% were white. Median CD4 cell count was 504 (IQR 350-672) cells/ml) and median HIV RNA level (available for 38% of the cohort) was 4.4 (IQR 3.7-4.9) log 10 copies/ml.
Of the 247 Kaposi's sarcoma events during the study period, there were 52, 138, 38, and 19 during the four calendar periods, respectively. The rates of Kaposi's sarcoma decreased over time ( Among the 247 Kaposi's sarcoma patients, 179 (72%) had a proximal CD4 cell count available. For the four calendar periods, the proximal CD4 cell count at Kaposi's sarcoma diagnosis was at least 350 cells/ml for 18, 7, 14, and 35%, respectively (P ¼ 0.01, Fig. 1 ). Participants with proximal CD4 cell count of less than 350 compared with at least 350 cells/ml at Kaposi's sarcoma diagnosis were more likely to have a prior non-Kaposi's sarcoma AIDS event (47 versus 9%, P < 0.001), diagnosed with HIV in the pre-HAART era (97 versus 83%, P ¼ 0.001), and spent a smaller percentage of time on antiretroviral therapy (median of 49 versus 62%, P ¼ 0.09); the two groups did not differ by demographics or HIV duration at the time of Kaposi's sarcoma diagnosis.
Among the 3422 participants with 20 263 person-years of follow-up since availability of HAART in 1996, 45 had Kaposi's sarcoma and a proximal CD4 cell count. From a proportional hazards model considering only timeupdated CD4 cell count, each incremental increase of 50 cells/ml decreased the risk of Kaposi's sarcoma by 30% (hazard ratio 0.70, 95% CI 0.64-0.76, P < 0.001). In a model with both CD4 cell count category and HAART use as time-updated covariates, compared with those with CD4 cell count of at least 350 cells/ml and on HAART, those with CD4 cell count of at least 350 cells/ml but not on HAART had an increased risk of Kaposi's sarcoma (hazard ratio 2.0, 95% CI 0.7-6.30, P ¼ 0.22) that did not reach statistical significance, whereas those with CD4 cell count of less than 350 cells/ml (regardless of HAARTuse) had an increased risk (hazard ratio 8.3, 95% CI 3.4-20.2, P < 0.001).
Our study demonstrates that although the Kaposi's sarcoma rates have declined during the HAART era and lower CD4 cell counts remain an important risk factor, a greater proportion of Kaposi's sarcoma cases are now occurring at higher CD4 cell counts. During the late HAART period, over one-third of Kaposi's sarcoma cases occurred at CD4 cell counts of at least 350 cells/ml. Clinicians should be aware of these trends and watchful for the occurrence of Kaposi's sarcoma despite robust CD4 cell counts.
The occurrence of Kaposi's sarcoma at higher than expected CD4 cell counts has been previously reported [9] [10] [11] [12] [13] . However, our study is unique in that we describe the changing trends of CD4 cell counts at Kaposi's sarcoma diagnosis over the entire HIV epidemic and demonstrate a rising proportion of cases at higher CD4 cell counts. To our knowledge, only one other study examined CD4 cell count trends at Kaposi's sarcoma diagnosis over time, but found no change in CD4 cell counts between the pre-HAART and post-HAART eras; however, their population had high rates of drug use and poor antiretroviral adherence [12] , whereas our population had free medical care, excellent reported medication adherence, and low rates of drug use (<1%) [14] .
Similar to other studies in the HAARTera [9, 10, 15] , 35% of our cases were on HAART and 9% had an HIV RNA level of less than 400 copies/ml at Kaposi's sarcoma diagnosis. Such cases are somewhat surprising because HAART has reduced the number of Kaposi's sarcoma cases by its effects on HIV suppression and potential antiangiogenic effects [10, 16] . Some Kaposi's sarcoma cases in the setting of HAART may be related to the immune reconstitution inflammatory syndrome [17, 18] ; however, most of our cases were not associated with the introduction of HAART.
Given these trends, determining whether HAART use at higher CD4 cell counts will reduce the impact of Kaposi's sarcoma is of clinical importance. We found a suggestion of increased risk of Kaposi's sarcoma among those not on HAART compared with those on HAART with CD4 cell counts of at least 350 cells/ml. Prior studies have shown that Kaposi's sarcoma in the setting of HAART results in less aggressive and more localized disease [19] .
In summary, Kaposi's sarcoma remains an important disease among HIV-infected persons, despite achievement of higher CD4 cell counts. Among patients with access to HAART, the proportion of Kaposi's sarcoma cases occurring at high CD4 cell counts appears to be rising. Future studies are needed to determine whether earlier HAART initiation will further decrease the burden of Kaposi's sarcoma among HIV-infected persons. Anemia is common in HIV infection, but the pathophysiology is poorly understood. Bone marrow analysis in 329 severely anemic (hemoglobin <5 g/dl) Malawian children with (n U 40) and without (n U 289) HIV infection showed that HIV-infected children had fewer CD34 R hematopoietic progenitors (median 10 vs. 15%, P U 0.04) and erythroid progenitors (2.2 vs. 3.4%, P U 0.05), but there were no differences in erythrocyte viability and maturation in later stages of erythropoiesis.
Despite an HIV-associated reduction in early red cell precursors, subsequent erythropoiesis appears to proceed similarly in HIV-infected and HIVuninfected children with severe anemia.
Anemia is the most common hematological complication in HIV-infected adults [1, 2] and is positively associated with disease progression [3] [4] [5] . In adults, anemia results primarily from reduced erythropoiesis [6] [7] [8] [9] . Information about anemia mechanisms in HIV-infected children is scarce [10] [11] [12] [13] and there have been no pediatric studies from sub-Saharan Africa.
We have previously reported that HIV infection was more common among severely anemic Malawian children than in a carefully selected control population (13 vs. 6%, P < 0.001) [14] . The aim of the present study was to determine whether HIV infection was associated with reduced erythroid precursor cells, or increased rates of apoptosis and dyserythropoiesis, and to investigate the role of cytokines, erythropoietin and plasma vitamin A in reducing apoptosis.
This study was part of a large case-control study investigating the causes of severe anemia in southern Malawi [14] . All children aged 6-60 months with a primary diagnosis of severe anemia (hemoglobin concentration <5 g/dl), and no blood transfusion within the previous month, were recruited prospectively between 2002 and 2004. HIV-uninfected children aged 6-60 months with no obvious signs of infection and undergoing elective operations were recruited as controls.
An automated full blood count, including reticulocytes, was performed on peripheral blood samples (Coulter counter, Beckman Coulter, Durban, South Africa). Malaria slides were read by two independent microscopists. Stained bone marrow aspirate smears from all children were used to determine the myeloid : erythroid ratio [15] and assess dyserythropoiesis, which was defined and scored according to a published protocol [16] .
C-reactive protein and erythropoietin were determined using a Roche p800/e170 system (Roche, Basel, Switzerland). Inflammatory cytokine profiles were measured by Cytometric Bead Array flow cytometry (FACS-Calibur, BD Biosciences, San Jose, California, USA). Serum vitamin A (retinol) was measured using HPLC [17] . HIV testing was performed using two rapid tests (Determine, Abbott-Laboratories, Tokyo, Japan; Unigold, Trinity-Biotech, Dublin, Ireland). Reactive results in children less than 18 months of age and discordant results were resolved by PCR [18] .
Fresh bone marrow aspirates underwent automated cell count (Coulter counter, Beckman Coulter) and four color flow cytometry (FACS-Calibur, BD Biosciences). Bone marrow cells were separated and incubated with different combinations of CD14-PE-Cy5 (Tük4), CD34-FITC/PE (QBEND/10), CD36-PE (CLB-IVC7), CD235a-FITC (CLB-AME-1) (all from Sanquin Reagents, Amsterdam, The Netherlands), laser dye styril-751 (LDS, Applied Laser Technology, Maarheeze, The Netherlands) and Annexin V and propidium iodide (IQ-products, Groningen, The Netherlands) [19] .
Patient characteristics and hematological variables were compared using the x 2 -test, Fisher's exact test, Student's t-test and the Mann-Whitney U-test. Correlations were assessed using the Pearson product-moment correlation coefficient or Spearman's rank correlation coefficient. A two-sided significance level was set at P ¼ 0.05.
Complete data (bone marrow samples and HIV tests) for this study were available for 329 of 381 children enrolled in our original case-control study. The original study had shown that bacteremia, malaria, hookworm, HIV, glucose-6-phosphate dehydrogenase (G6PD ) deficiency and vitamin A and B 12 deficiency were associated with severe anemia. Iron deficiency was negatively associated with severe anemia. Folate deficiency and sickle cell disease were uncommon [14] .
Forty of the 329 children (12%) were infected with HIV. Their median age was 25 months compared with 16 months for HIV-uninfected children (P < 0.01). No significant differences were found between HIV-infected and uninfected children with regard to other baseline characteristics, mean hemoglobin levels (P ¼ 0.67) or other erythrocytic indices (Table 1 ) [20] .
HIV-infected children had fewer bone marrow CD34 þ hematopoietic progenitors, erythroid progenitor cells and erythroid precursor cells than HIV-uninfected children, but numbers of bone marrow proerythroblasts, basophilic and polychromatic erythroblasts and peripheral blood reticulocytes were similar (Table 1 ). Correction for age or malaria did not alter the results (data not displayed).
Dyserythropoiesis occurred in 2.8% and 3.8% of erythroid precursors in HIV-infected and uninfected children, respectively (P ¼ 0.12, Table 1 ). The proportions of viable erythroid precursor cells and those at various stages of apoptosis were similar between the two groups ( Table 1 ). The proportions of dyserythropoietic cells and red cells undergoing early apoptosis were positively correlated (range r ¼ 0.34, P ¼ 0.01). There were no correlations (r ¼ À0. 14-0.15 ) between the proportion of either dyserythropoietic or apoptotic cells and the peripheral blood concentrations of cytokines tumor necrosis factor-a (P ¼ 0.90 and 0.28), interferon-g (P ¼ 0. This study is the first detailed prospective analysis of erythropoiesis using bone marrow samples and flow cytometry in HIV-infected children. HIV-infected Wasting was defined as a weight for height Z-score of less than À2 [20] . Dyserythropoiesis was defined as multinuclearity, karyorrhexis, intercellular chromatin bridging or incomplete mitoses. Early apoptosis refers to the expression of phosphatidylserine only, whereas in late apoptosis also propidium iodide was detected. In viable cells neither of these dyes were detected [19] . LDS was used to stain DNA. CRP, C-reactive protein; IQR, inter quartile range; LDS, laser dye styril-751; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PI, propidium iodide; RDW, red cell distribution width.
M P-value refers to the difference between HIV-infected and uninfected children.
children with severe anemia had 33% fewer CD34 þ hematopoietic progenitors and 35% less erythroid progenitors in their bone marrow than uninfected children. This supports the hypothesis that red cell production failure is an important cause of severe anemia in HIVinfected children and may be caused by a reduced stem cell capacity [21] . However, the proportion of more mature erythroid precursor cells in bone marrow or peripheral blood (reticulocytes) did not differ between the two groups, suggesting that HIV-uninfected children had less efficient later stages of erythropoiesis than HIVinfected children. This is supported by the trend toward less dyserythropoiesis and apoptosis in HIV-infected children, but is in contrast to previous reports suggesting that anemia due to dyserythropoiesis is more common in later stages of HIV disease [2, 10] . Alternatively, the lost CD34 cells in HIV-infected children may have been precursors that were not committed to erythropoiesis.
HIV infection affects hematopoietic processes possibly through abnormal expression of cellular genes and cytokines [22] . The African HIV-1 subtype C can directly infect CD34 þ hematopoietic progenitors [23] . Unlike previous studies [24, 25] , we found no association between dyserythropoiesis or apoptosis and altered cytokine levels or vitamin A deficiency [26, 27] , despite 90% of children having vitamin A deficiency [14] . More intensive investigations might identify cytokines that affect regulatory signals and could potentially be therapeutic targets to reduce hemopoietic inhibition in HIV patients.
In common with previous studies, we did not find any differences in peripheral blood erythrocytic indices or bone marrow microscopy in HIV-infected compared with uninfected children [6] [7] [8] 10, 28] , possibly because of the multifactorial cause of anemia in African children [14, 29] .
None of the children were on antiretroviral therapy, which can exacerbate blood and bone marrow abnormalities [30] . Although not all tests were done on all children, the large sample size increases confidence that the study sample was representative.
The findings in these severely anemic Malawian children indicate that despite an HIV-associated reduction in early red cell precursors, subsequent erythropoiesis appears to proceed similarly in HIV-infected and HIV-uninfected children with severe anemia. Immune changes induced by the CCR5 antagonist maraviroc raise the question of an impairment of responses to vaccines. We evaluated the immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine in HIV-1-infected patients with suppressed HIV viremia with or without a maraviroc-containing regimen. Seroprotection, seroconversion, and geometric mean titer ratio of specific antibody titers did not differ between groups. These results suggest that maraviroc does not significantly affect the immune response to this adjuvanted vaccine.
Maraviroc (MVC) blocks HIV-1 entry into the CD4 host cells [1] by binding to the chemokine receptor CCR5. Several studies have shown an increased severity of West Nile virus infection and tick-borne encephalitis virus in patients with the CCR5D32 deletion [2, 3] , suggesting a key role of CCR5 in immune control of viruses. In mice, a CCR5 gene deletion is associated with a more severe influenza infection [4] . Because CD4 þ CCR5 þ T cells of memory phenotype help with differentiation of B cells into antibody producing plasma cells and help CD8 antiviral effector T cells, MVC may influence immune response to live or attenuated viruses. These observations led some authors to recommend avoiding yellow fever vaccination in HIV-1-infected patients treated with MVC [5] . However, the MVC immunomodulatory effects on responses to vaccines remain unknown. Although one dose of the 2009 pandemic influenza A-H1N1v adjuvanted vaccine had been shown to trigger a protective antibody response to influenza in HIV-1 patients [6] , concerns were raised about a possible interference of MVC treatment with responses to this highly immunogenic vaccine.
To test such hypothesis, we conducted a prospective case-control study to compare the humoral immunogenicity of the adjuvanted pandemic influenza A-H1N1v 2009 vaccine. HIV-1 patients on combined antiretroviral therapy (cART) containing MVC (MVC group) or not (control group) were studied after providing informed consent according to ethical recommendations.
All patients had to be on cART with a viral load less than 50 copies/ml. Control patients were matched for sex, age (AE5 years), and CD4 cell counts (AE75 cells/ml). All patients received one dose (3.75 mg hemagglutinin) of the 2009 Pandemrix influenza A-H1N1v adjuvanted vaccine at day 0 (D0) between 23 November 2009 and 4 January 2010. Influenza-specific antibody titers were measured at D0 and D21 by using a hemagglutination inhibition assay (HIA) modified from Kendal and Skehel [7] by the use of human O Rh-red blood cells and the nonadjuvanted influenza A-H1N1v 2009 vaccine Panenza as antigen.
Immunogenicity was evaluated upon percentages of seroprotection (antibody titers !1/40), seroconversion (antibody titers <1/10 to !1/40) or four-fold increase in antibody titers, and geometric mean titer (GMT) ratio (D21/D0). Any clinical events, changes in CD4 cell counts, and HIV viral load were recorded.
We included 22 patients in the MVC group and 29 in the control group. Baseline characteristics were similar between both groups and showed a vast majority of men (86 and 93%), a median (min-max) age of 50 (40-74) and 53 (37-78) years, and a median CD4 cell count of 459/ml (41-1002) and 520/ml (115-1065) in the MVC and the control groups, respectively. Patients had been infected for a median duration of 20 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) in the MVC group and À12/ml (À282-591) in the control group. All patients remained aviremic with a viral load less than 50 copies/ml at D21 except for two patients who experienced a blip at week 4 that was subsequently suppressed.
Influenza immunogenicity analysis showed seroprotection at D0 in four of 51 patients (two in the MVC and two in the control group, Fig. 1a ). Patients who received the seasonal influenza vaccine before the pandemic one had a higher baseline antibody GMT for influenza A-H1N1v virus than nonseasonal vaccinated patients: 17 to the antibody response to the pandemic vaccine. Finally, the duration of exposure to MVC did not significantly influence the response to this adjuvanted vaccine.
Our study showed that MVC did not significantly affect the antibody response to the influenza A-H1N1v adjuvanted vaccine in HIV-1-infected patients despite a slightly lower antibody levels in patients receiving MVC. In addition, this influenza A-H1N1v adjuvanted vaccine showed a good immunogenicity and a good tolerance in HIV-1 patients, with a persisting undetectable viral load while on cART. Noteworthy, the seasonal influenza vaccine may have conferred some protection to the pandemic A-H1N1v virus, suggesting a cross-reactivity between the pandemic A-H1N1v and the A-H1N1/ Brisbane/59/07 strain contained in the seasonal vaccine.
Altogether these results, observed, however, in a small series of patients, suggest that the MVC CCR5 antagonist does not impair the response to influenza vaccines in stably suppressed HIV-1-infected patients with subnormal CD4 cell counts. It remains to be determined whether such a lack of negative immunomodulatory effect of CCR5 antagonists reflects the strong immunogenicity of this adjuvanted vaccine or can be extrapolated to any vaccine preparation.
